Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

A-940894 shows potent in vivo/in vitro anti-inflammatory activity

Oct. 19, 2009

Anti-Fas IgM monoclonal antibody ARG-098 decreases rheumatoid arthritis activity

Oct. 19, 2009

Selective glucocorticoid receptor modulator has less effect on bone biomarkers

Oct. 19, 2009

Medarex releases full phase II results with MDX-100 in rheumatoid arthritis

Oct. 19, 2009

Moxaverine increases ocular blood flow in macular degeneration, glaucoma patients

Oct. 19, 2009

ADC-4022 given with budesonide protects lung function in COPD patients

Oct. 19, 2009

BIBW-2948 not well tolerated in 4-week chronic obstructive pulmonary disease study

Oct. 19, 2009

Phase II data show that QVA-149 is safe and improves bronchodilation in COPD

Oct. 16, 2009

Sivelestat shows safety in clinical evaluation in IVIG-resistant Kawasaki disease

Oct. 16, 2009

Randomized trial suggests preventive role of probucol in contrast-induced acute kidney injury

Oct. 16, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...